Coherus Oncology, Inc. Logo

Coherus Oncology, Inc.

Biopharmaceutical company developing and commercializing immuno-oncology therapies.

CHRS | US

Overview

Corporate Details

ISIN(s):
US19249H1032
LEI:
Country:
United States of America
Address:
C/O DENNIS M. LANFEAR, 94065 REDWOOD CITY

Description

Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies. The company advances a diversified portfolio of next-generation treatments to improve outcomes for patients with cancer, particularly those with hard-to-treat tumors. Its key commercial product is LOQTORZI® (toripalimab-tpzi), a next-generation PD-1 inhibitor. LOQTORZI® is the only therapy approved by the U.S. FDA for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC), used either as a single agent or in combination with chemotherapy. Coherus's clinical pipeline includes multiple drug candidates that target the tumor microenvironment.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-06-14 00:48 English ZIP 7.2 KB
2025-06-14 00:48 English ZIP 7.1 KB
2025-06-14 00:47 English ZIP 7.1 KB
2025-06-14 00:46 English ZIP 7.2 KB
2025-06-13 22:07
FORM 8-K
English ZIP 68.4 KB
2025-05-30 22:05
8-K
English ZIP 212.3 KB
2025-05-28 23:12 English ZIP 7.5 KB
2025-05-12 22:59
10-Q
English ZIP 2.0 MB
2025-05-12 22:39
8-K
English ZIP 147.3 KB
2025-05-09 23:59 English ZIP 7.2 KB
2025-05-09 23:58 English ZIP 7.2 KB
2025-04-29 22:09
ARS
English ZIP 2.1 MB
2025-04-29 22:07
DEFA14A
English ZIP 469.9 KB
2025-04-29 22:05
DEF 14A
English ZIP 1.5 MB
2025-04-25 22:05
8-K
English ZIP 77.5 KB

Automate Your Workflow. Get a real-time feed of all Coherus Oncology, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Coherus Oncology, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Coherus Oncology, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.